TY - JOUR
AU - Stafford, Diane, E.J.
AB - Downloaded from http://journals.lww.com/co-endocrinology by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW URRENT Prader Willi syndrome: endocrine updates and new PINION medical therapies a b Rebecca M. Harris and Diane E.J. Stafford Purpose of review Prader Willi syndrome is characterized not only by hyperphagia frequently resulting in obesity, but also by endocrine dysfunction across a variety of axes. This article reviews the most recent literature regarding possible causes of hyperphagia and the nature of endocrinopathies seen in Prader Willi syndrome, as well as current research into possible therapies. Recent findings Investigation into neurologic, metabolic and hormonal drivers of hyperphagia and obesity has revealed new insights and clarified underlying pathophysiology. Additional studies continue to elucidate the hormonal deficiencies seen in the syndrome, allowing for improvements in clinical care. Summary The underlying causes of the hyperphagia and progressive obesity frequently seen in Prader Willi Syndrome are largely unknown and likely multifactorial. Understanding the hormonal and metabolic drivers at work in PWS, as well as the nature of other hormonal dysfunction seen in the syndrome is necessary to guide current management and future research directions. Keywords endocrinology, hyperphagia, obesity, Prader Willi syndrome INTRODUCTION recent literature pertaining to metabolic and endo- crine function in PWS and highlight 
TI - Prader Willi syndrome: endocrine updates and new medical therapies
JO - "Current Opinion in Endocrinology, Diabetes & Obesity"
DO - 10.1097/MED.0000000000000517
DA - 2020-02-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/prader-willi-syndrome-endocrine-updates-and-new-medical-therapies-et99mLiZof
SP - 56
VL - 27
IS - 1
DP - DeepDyve
ER -